Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this is a Phase 3 trial testing apremilast specifically in children with Behçet's disease oral ulcers, what does my doctor think about the existing adult safety and effectiveness data for apremilast, and how much of that might apply to my child's situation?
2. 2The trial measures the total number of oral ulcers over the first 12 weeks — what would it mean for my child to go 12 weeks being closely monitored while on an experimental dosing regimen, and is there a standard treatment that might provide more predictable relief in the meantime?
3. 3Since this study is still actively recruiting, what is my doctor's sense of whether the trial sites are nearby, and what would the visit schedule realistically look like for our family over those 12 weeks and beyond?
4. 4Are there any eligibility requirements related to how active my child's oral ulcers need to be, or other treatments they may have already tried, that my doctor thinks could affect whether this trial is even worth pursuing for us?
5. 5If my child enrols and the apremilast doesn't seem to be helping during the trial, what options would be available to switch to a different treatment, and would participation affect access to other therapies afterward?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.